Rorive Sandrine, Maris Calliope, Debeir Olivier, Sandras Flavienne, Vidaud Michel, Bièche Ivan, Salmon Isabelle, Decaestecker Christine
Laboratory of Pathology, Erasmus University Hospital, The Netherlands.
J Neuropathol Exp Neurol. 2006 Aug;65(8):794-807. doi: 10.1097/01.jnen.0000228203.12292.a1.
Although World Health Organization (WHO) grade I pilocytic astrocytomas and grade II diffuse astrocytomas have been classified for decades as different clinicopathologic entities, few, if any, data are available on the biologic features explaining these differences. Although more than 50 microarray-related studies have been carried out to characterize the molecular profiles of astrocytic tumors, we have identified only 11 that provide sound data on low-grade astrocytomas. We have incorporated these data into a comparative analysis for the purpose of identifying the most relevant molecular markers characterizing grade I pilocytic and grade II diffuse astrocytomas. Our analysis has identified various interesting genes that are differentially expressed in either grade I or grade II astrocytomas when compared with normal tissue and/or high-grade (WHO grade III and IV) astrocytomas. A large majority of these genes encode adhesion, extracellular matrix, and invasion-related proteins. Interestingly, a group of 6 genes (TIMP4, C1NH, CHAD, THBS4, IGFBP2, and TLE2) constitute an expression profile characteristic of grade I astrocytomas as compared with all other categories of tissue (normal brain, grade II, and high-grade astrocytomas). The end products (proteins) of these genes act as antimigratory compounds, a fact that could explain why pilocytic astrocytomas behave as compact (well-circumscribed) tumors as opposed to all the other astrocytic tumor types that diffusely invade the brain parenchyma. Having validated these molecular markers by means of real-time reverse transcriptase-polymerase chain reaction, an integrated model was proposed illustrating how and why pilocytic astrocytomas constitute a distinct biologic and pathologic entity when compared with diffuse astrocytomas.
尽管世界卫生组织(WHO)将I级毛细胞型星形细胞瘤和II级弥漫性星形细胞瘤归类为不同的临床病理实体已有数十年,但关于解释这些差异的生物学特征的数据却很少,即便有也寥寥无几。虽然已经开展了50多项与微阵列相关的研究来表征星形细胞肿瘤的分子谱,但我们仅发现11项研究提供了关于低级别星形细胞瘤的可靠数据。为了确定表征I级毛细胞型和II级弥漫性星形细胞瘤的最相关分子标志物,我们将这些数据纳入了一项比较分析。我们的分析确定了各种有趣的基因,这些基因在与正常组织和/或高级别(WHO III级和IV级)星形细胞瘤相比时,在I级或II级星形细胞瘤中差异表达。这些基因中的绝大多数编码粘附、细胞外基质和侵袭相关蛋白。有趣的是,与所有其他组织类别(正常脑、II级和高级别星形细胞瘤)相比,一组6个基因(TIMP4、C1NH、CHAD、THBS4、IGFBP2和TLE2)构成了I级星形细胞瘤的表达谱特征。这些基因的终产物(蛋白质)起到抗迁移化合物的作用,这一事实可以解释为什么毛细胞型星形细胞瘤表现为致密(边界清晰)的肿瘤,而不是像所有其他弥漫性侵袭脑实质的星形细胞肿瘤类型那样。通过实时逆转录聚合酶链反应验证了这些分子标志物后,我们提出了一个综合模型,阐明了与弥漫性星形细胞瘤相比,毛细胞型星形细胞瘤如何以及为何构成一个独特的生物学和病理学实体。